SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is selling off with memory stocks amid concerns that Chinas CXMT is advancing a new DRAM design and could add competitive supply, alongside broader doubts about AI-related chip demand. Traders disagree on whether the news threatens SanDisks NAND business directlysome call the selloff an indiscriminate sector reaction and buy the dip, while others fear oversupply and an unwind in the AI trade.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel shares are caught in a sharp pullback alongside semiconductor stocks, with traders citing AI-spending concernsincluding questions about OpenAIs revenue outlook and the cost of financing data-center investment. Intel-specific frustration centers on the lack of confirmed external foundry customers and uncertainty around Terafab, while some traders view the selloff as an oversold sector correction and look for support near the $100 level.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Concerns that Chinese chipmaker CXMTs progress in advanced DRAM could increase competition and pressure future memory pricing have weighed on Micron and other memory stocks. Traders are divided: some see a longer-term threat, while others argue CXMTs technology is unproven and unlikely to challenge Microns high-bandwidth memory business soon.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins pullback and persistent selling pressure are driving discussion, with traders split between expecting a break lower and treating the decline as a buying opportunity near support. Some point to ETF outflows, rising yields, and a stronger dollar as headwinds, while others argue the move is a normal consolidation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, with traders pointing to weakness in memory-chip names and continued negative momentum, is driving attention to SOXL. The community is divided between buying the dip on confidence in chip demand and warning that the decline could deepen, especially given the ETFs amplified exposure to semiconductor moves.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

Recent analyst downgrades and lowered price targets are drawing attention as shares extend a steep decline toward yearly lows ahead of earnings. Traders debate whether the weakness reflects rate and valuation concerns or short-selling, while bullish holders point to SoFis growth and view the pullback as a buying opportunity.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells Investor Day outlook for accelerating AI data-center growth and expanded custom-silicon and connectivity opportunities remains the main focus, alongside a wave of analyst upgrades. Traders are split between viewing the long-term targets as bullish and calling the event a short-term letdown, with profit-taking and broader semiconductor weakness weighing on the shares.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is falling with AI infrastructure and neocloud peers amid renewed concerns about the AI trade, including reports that OpenAIs annualized revenue was below figures previously circulated. Traders dispute whether the report signals weaker demand or reflects differing accounting methods, with bears expecting more downside and bulls treating the selloff as an overreaction and buying dips.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Reports that OpenAIs latest high-speed model feature uses Nvidia GPUs rather than Cerebras hardware have sharpened concerns about Cerebras reliance on OpenAI, while traders also cite an approaching share unlock as a potential source of selling pressure. The selloff has divided the community between bears focused on customer concentration and share supply and bulls who view the decline as an overreaction and are buying the dip.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is drawing attention amid a sharp KOSPI selloff, with traders linking pressure to concerns that Chinese chipmaker CXMTs planned advanced DDR5 production could challenge Samsung and SK Hynix in memory. The community disputes how credible that competitive threat is, while debating whether the leveraged ETFs steep decline is a buying opportunity or part of a broader unwind.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.

Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children...

If You Invested $100 In Vertex Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 10.96% on an annualized basis producing an average annual return of 23.3%. Currently, Vertex Pharmaceuticals has a marketread more...

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1...

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know  

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAmgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow...

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders...

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.

Key PointsVertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder  

Equity

Neutral Sentiment

Beats across the board

Mostly beats

Mostly misses

Misses across the board

What do you expect from big bank earnings this week?

Stocktwits

Stocktwits Polls

$VRTX $XBI  $IBRX 
Not a single 💙 on my VRTX Posts.   I’m either suppressed here, or have NO fans.    

Makes me wonder.   Few Posters have been more right about VRTX than me.   By the way, IBRX is a Vertex in the making.   ImmunityBio is unstoppable! 

Regardless, Grok knows!

S Olsen

$VRTX This analyst didn’t miss the ‘Overton’ window.   As in the new FDA Chiefs background in ‘Pain’.

$VRTX why is this beaten to death??? They should do some buybacks.

Management has to wake up.

Smart Trader

$VRTX $-Billions!  
Don’t be distracted….Pove!  Pain too- overdue for a Trial update! 

Sorry if these are not in order.

$VRTX OptionsFLO flow and daily chart read. The alert snapshot shows $436K in the Oct 16 $525 puts. Volume was 17.5x standing open interest at capture. Daily chart through Sep 25: last close $526.19, below its 20 day average and above its 50 day average, with RSI at 53. The 3 month range is $465.00 to $560.25. Intraday volume does not establish whether a position was opened or held; the next settled open interest is the check.

PredictionFLO

$VRTX JOURNAVX: 535K Q2 scripts → only $50M revenue. WAC ~$15.50/tablet while common generic pain meds cost pennies — yet PBM/Medicare access keeps expanding. 
 
PBM-engineered access, not some miracle-demand story. Ask pharmacists how many overpriced “next big thing” drugs get pushed for a year, then vanish into formulary oblivion. 
 
Wall Street calls it a blockbuster. Pharmacy has seen this movie before. NEXT STOP  $476 🔥

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRTX Vertex Pharmaceuticals, Inc.

Fundamentals

Latest VRTX News